Rescue therapy for patients with anti-PD-1-refractory Merkel cell carcinoma: a multicenter, retrospective case series
Author:
Publisher
BMJ
Subject
Cancer Research,Pharmacology,Oncology,Molecular Medicine,Immunology,Immunology and Allergy
Link
http://link.springer.com/content/pdf/10.1186/s40425-019-0661-6.pdf
Reference24 articles.
1. Chan IS, Bhatia S, Kaufman HL, Lipson EJ. Immunotherapy for merkel cell carcinoma: a turning point in patient care. J Immunother Cancer. 2018;6:23. https://doi.org/10.1186/s40425-018-0335-9 .
2. Nghiem PT, Bhatia S, Lipson EJ, Kudchadkar RR, Miller NJ, Annamalai L, et al. PD-1 blockade with pembrolizumab in advanced merkel-cell carcinoma. N Engl J Med. 2016;374:2542–52.
3. D'Angelo SP, Russell J, Lebbe C, Chmielowski B, Gambichler T, Grob JJ, et al. Efficacy and safety of first-line avelumab treatment in patients with stage IV metastatic merkel cell carcinoma: a preplanned interim analysis of a clinical trial. JAMA Oncol. 2018;4:e180077.
4. Kaufman HL, Russell JS, Hamid O, Bhatia S, Terheyden P, D'Angelo SP, et al. Updated efficacy of avelumab in patients with previously treated metastatic merkel cell carcinoma after >/=1 year of follow-up: JAVELIN merkel 200, a phase 2 clinical trial. J Immunother Cancer. 2018;6:7. https://doi.org/10.1186/s40425-017-0310-x .
5. Topalian SL, Bhatia S, Kudchadkar RR, Amin A, Sharfman WH, Lebbe C, et al. Nivolumab (nivo) as neoadjuvant therapy in patients with resectable merkel cell carcinoma (MCC) in CheckMate 358. JCO. 2018;36:9505. https://doi.org/10.1200/JCO.2018.36.15_suppl.9505 .
Cited by 43 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Merkel Cell Carcinoma;Hematology/Oncology Clinics of North America;2024-10
2. Merkel cell carcinoma: updates in tumor biology, emerging therapies, and preclinical models;Frontiers in Oncology;2024-07-29
3. Systemic Therapy for Non-Melanoma Skin Cancers: Latest Advances;Current Oncology Reports;2024-07-02
4. Merkel cell carcinoma refractory to anti-PD(L)1: utility of adding ipilimumab for salvage therapy;Journal for ImmunoTherapy of Cancer;2024-07
5. First-line avelumab treatment in patients with metastatic Merkel cell carcinoma: 4-year follow-up from part B of the JAVELIN Merkel 200 study;ESMO Open;2024-05
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3